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1078–5884/00Long-term Results of Above Knee Femoro-popliteal Bypass
Depend on Indication for Surgery and Graft-material
J. Berglund,1 M. Bjo¨rck,2 J. Elfstro¨m1* and On behalf of the SWEDVASC
Femoro-popliteal Study Group**Departments of 1Thoracic and Vascular Surgery, University Hospital of Linko¨ping, Linko¨ping, and 2Surgery,
Uppsala University Hospital, Uppsala, SwedenObjective. To determine the long-term results of above-knee femoro-popliteal bypass with autologous saphenous vein (SV)
or expanded polytetrafluoroethylene (ePTFE) in routine surgical practice.
Methods. Data from the Swedish vascular registry, Swedvasc was reviewed retrospectively. Patients with bypass surgery in
1996 and 1997 were assessed 5–7 years later. Data were gathered from the case-records and from clinical follow-up. The
composite endpoint of graft failure included death within 30 days, occlusion, major amputation, extension of the graft to
below-knee position and removal of an infected graft. Kaplan–Meier curves and Cox’ proportional hazard ratios were
calculated.
Results. Four hundred and ninety-nine patients undergoing bypass for critical limb ischemia (CLI) (56%) or claudication
(44%), SV (28%) or ePTFE (72%), were included. There were no significant differences in patient characteristics between
patients with SV or ePTFE. CLI and ePTFE were risk factors for graft failure. For patients with both claudication and CLI
SV grafts yielded better long-term results than ePTFE grafts (p!0.03) and (p!0.003), respectively. Symptom aggravation
after graft occlusion was almost exclusively restricted to ePTFE grafts.
Conclusions. Femoro-popliteal bypass above-knee with SV gives good long-term results, especially for claudication. ePTFE
grafts cannot be recommended in claudicants, since occlusion occurs often and frequently leads to CLI.Keywords: Popliteal artery; Intermittent claudication; Critical ischemia; Blood vessel prosthesis implantation; Surgery
operative.Introduction
Bypass to the popliteal artery above the knee is a
standard procedure, but the indications for this
operation and which graft-material to use remain
controversial issues. For above-knee bypass, the use of
expanded polytetrafluoroethylene (ePTFE) is claimed
to be as efficient as the use of autologous saphenous
vein (SV). A Cochrane review concluded that thereing author. Johan Elfstro¨m, Department of Thoracic
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ePTFE as a conduit for a bypass in this location.1
Another recent review concluded that primary
patency was superior after vein bypass compared to
ePTFE.2 However, the article did not analyse the
influence on patency of different indications for the
procedure. Five randomized controlled trials (RCTs)
have been published with differing results.3–7 Three of
the studies showed no significant difference between
graft materials after 4–5 years,3,4,7 whereas the other
two RCTs showed no difference up to 2 years but a
significant advantage for SV thereafter,4,6 Most of these
studies suffered from small sample size and very few
patients were eligible to 5-year follow-up. Further-
more, two of these studies were performed on patients
with claudication only4,7 and in the remaining RCTs
the number of patients was not sufficient to permit a
meaningful subgroup analysis to compare patients
with critical ischemia vs. those with claudication.
RCTs are not the only way to evaluate the outcome ofEur J Vasc Endovasc Surg 29, 412–418 (2005)
doi:10.1016/j.ejvs.2004.12.023, available online at http://www.sciencedirect.com onved.
Long-term Results of AK Femoro-popliteal Bypass 413surgery. Recent retrospective studies have challenged
the effectiveness of synthetic bypass to the popliteal
artery above the knee.8,9
In the Swedish vascular registry (Swedvasc), more
than 90% of all vascular surgery is registered pro-
spectively for more than 10 years.10 A large number of
unselected patients operated on in routine surgical
care, with a minimum of 5-year follow-up, are
available for study. The overall aim of the present
study was to evaluate the results of the procedure in
routine surgical care against the background of results
reported from RCTs.
The specific aims were to answer the four questions:
(i) what is the long-term patency with the two graft
materials, (ii) do the long-term results differ depend-
ing on the indication for surgery, (iii) can risk factors
predictive of failure/occlusion be identified and (iv)
what are the consequences of a failed procedure.Patients and Methods
Twenty-three hospitals in Sweden entered patients.
These hospitals constitute 66% of all hospitals per-
forming vascular surgery in Sweden. The Swedvasc
registry was searched for all femoro-popliteal
bypasses to the popliteal artery above the knee,
which were performed in these hospitals in the years
1996 and 1997. Among 555 patient records, 499 (90%)
with available records were studied. There were 56
further patients in the Swedvasc registry, whose
records could not be retrieved and those were
analysed separately, with use of data prospectively
reported to the registry.
The analysis was performed between July 2002 and
June 2003, i.e. 5–7 years after the operation. Case-
records from the surgical and orthopaedic depart-
ments were reviewed and the intention was to
re-examine all surviving patients without notification
of an occlusion.
Thirty-nine characteristics (Table 1) for each patient
were retrieved from the medical records and/or
clinical follow-up. Results for 30 days, 1 year and at
the time of the investigation were obtained. A graft
was considered patent if there were clearly palpable
distal pulses or pulse in a subcutaneous graft.
Otherwise a duplex examination was requested. For
dead patients, without a recorded occlusion, the graft
was considered patent until the latest relevant exam-
ination that verified a patent graft, and follow-up was
defined until that time-point.
Among the 303 surviving patients at the end of the
study, 254 (84%) either had an occlusion registered in
the case-records or were re-examined. The 49 patientswho did not attend the clinical follow-up most were in
poor health due to advanced age or co-morbid
conditions or lived remote from the hospital. If a
living patient, with no record of graft occlusion, did
not attend for clinical follow-up we used the same
definition for patency and follow-up period as for the
deceased patients, i.e. follow-up ceased at the last
verification of a patent graft in the patient records.
The composite end-point of graft failure included
the following events:1. Death within 30 days.
2. Graft occlusion.
3. Removal of an open graft due to infection.
4. Extension of the graft to below-knee position.
5. Amputation at below knee level or higher.
Surgical revisions and endoluminal dilatations of
remaining valves or fistulae and of strictures were not
class as procedure failure. Therefore, the principal
outcome measure was assisted primary patency or
addition of death within 30 days of operations.
The data were stored in a Microsoft Accesse
database and the Statisticae package was used for
the calculations. Kaplan–Meier survival analysis was
used together with the log-rank method for evaluation
of significance. Independent variables predicting out-
come or graft failure were identified by multivariate
analysis through forward stepwise regression analysis
and Cox’s proportional hazard ratios. Categorical
variable were analysed by c2 tests.Results
The 499 patients included in the study had a median
age of 73 years (range 42–96) and 88 (18%) were above
80 years of age at the time of the operation. The
majority of patients (55%) were men. Women were
slightly older (median 75 years) than men (72). Most
patients (56%) were treated for critical ischemia but
claudication was also common (44%). Twenty-eight
percent of the patients had a SV graft and the
remainder ePTFE. The proportion of SV grafts was
similar among patients undergoing surgery for clau-
dication and critical ischemia (Table 2). There were no
significant differences in patient characteristics or in
indications for surgery between the patients receiving
SV or ePTFE grafts (Tables 2 and 3). Poor run-off
(defined as 0 or 1 open crural artery) was more
common in critical ischemia than in claudication (49
vs. 27%, p!0.001).Eur J Vasc Endovasc Surg Vol 29, April 2005
Table 1. Variables and definitions
Variable Definitions and/or values
Personal id number
Name
Sex
Side
Indication Claudication, rest pain or ulcer/small gangrene
Urgency Planned or urgent
Order of procedure same location Primary or secondary
Risk factors
Cerebrovascular disease Previous stroke or TIA
Diabetes
Hyperlipemia
Hypertension
Cardiac disease Coronary disease, atrial fibr., heart failure, valve disease
Pulmonary disease
Renal disease Serum creatinineO150 mg/l
Smoking
Number of open crural arteries Visible on angiography down to the ankle
Date of operation
Graft material ASV or ePTFE
Postoperative bleeding
Graft infection
Reoperation due to Either open or endovascular procedure
Remaining valve of fistula
Stricture
Anastomotic narrowing
Latest date of open graft
Date of death
Date of occlusion
Symptoms after occlusion Claudication converted to critical ischemia or not
Urgent reoperation after occlusion
Date of amputation
J. Berglund et al.414Mortality
Seven patients (1.4%) died within 1 month. At 1 year,
52 patients (10%) had died and by the end of the
observation period 196 patients (39%) had died.
Among patients above the age of 80 the mortality
was 23% at 1 year and 65% at the end of the
observation period. Almost 60% of these elderly
patients lived more than 3 years.Table 3. Characteristics of the patient groups (within brackets
percentage of each column containing 139 SV and 360 PTFE
patients, respectively)
All patients
(NZ499)
SV (NZ139) PTFE
(NZ360)
Female sex 224 62 (45%) 162 (45%)
Mean age GSD 71G9 72G10 71G9Early complications
During the first postoperative month there were 26
(5.2%) occlusions. Postoperative bleeding occurred in
3.4% and infection in 1.8%. Early complication rates
were independent of graft material. Later 40 patientsTable 2. Indications in relation to graft material (within brackets
percentage within each row)
All patients SV ePTFE
Claudication 220 55 (25%) 165 (75%)
Rest pain 107 34 (32%) 73 (68%)
Ulcer/gangrene 172 50 (29%) 122 (71%)
All 499 139 (28%) 360 (72%)
Eur J Vasc Endovasc Surg Vol 29, April 2005underwenta revision for failinggraft eitherwithanopen
or an endovascular procedure: 22 had vein grafts and 18
had ePTFE and thus the frequency of revision was
higher among SV-patients (16 vs. 5%; pZ0.0003).
However, the graft patency at the end of the observation
period was not increased by graft revision (53% for
primary assisted patency vs. 60% for primary patency;
pZ0.36).Above 80 years (%) 88 26 (19%) 62 (17%)
Cerebrovasc. disease 58 18 (25%) 40 (11%)
Heart disease 260 68 (49%) 192 (53%)
Diabetes mellitus 153 44 (32%) 109 (30%)
No. of open crural arteries
0 36 14 (10%) 22 (6%)
1 161 45 (32%) 116 (32%)
2 or 3 257 72 (52%) 185 (51%)
Urgent operation 39 13 (9%) 26 (7%)
Previous femoro-
popliteal procedure
63 21 (15%) 42 (12%)
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At the end of follow-up 203 grafts (41%) had failed,
according to our definition, (Table 4). Only two risk
factors for failure were identified, namely graft
material and the indication for surgery; poor run-off
and urgent operation did not quite achieve statistical
significance. The Cox proportional hazard ratios for
these variables are shown in Fig. 1.
The success rate, according to indication for
surgery, is shown in Fig. 2, with both types of graft
material included. The success rate was higher for
patients with claudication than for patients with
critical ischemia (pZ0.0022). The influence of the
graft material on success rate according to indication
for surgery is shown in Figs. 3 and 4. SV grafts
performed better than ePTFE grafts in both situations
(in critical ischemia pZ0.031; Fig. 3, and in claudica-
tion pZ0.0027; Fig. 4). Early results were similar but
the curves separated after 6 months in patients with
critical ischemia and after 1 year among patients with
claudication.
A subgroup analysis of 88 patients above 80 years of
age was performed. In this group, there were more
women and cardiac disease was more common. The
distribution of SV and ePTFE grafts was not different
from that in the entire study. The proportion of failures
was not greater than in younger patients (36 vs. 42%;
pZ0.36). There was no significant difference between
SV or ePTFE grafts, perhaps due do the small number
of patients (pZ0.29, power 27%). The indication for
surgery did not appear to influence results.Symptom aggravation after a graft occlusion
Among the 220 patients undergoing surgery for
claudication graft failure occurred in 79 patients. InTable 4. Adverse events at the end of follow-up (within brackets
percentage of each column containing 139 ASV and 360 PTFE
patients, respectively)
All patients SV (nZ139) PTFE
(nZ360)
Revisions 40 22 (16%) 18 (5%)
Graft infection 9 3 (2%) 6 (2%)
Postoperative
bleeding
17 10 (7%) 7 (2%)
Death within 30 days 7 2 (1.4%) 5 (1.4%)
Death at follow-up 196 61 (44%) 135 (38%)
Occlusions 172 30 (22%) 142 (39%)
Aggravation after
occlusion*
32 1 31
Urgent reoperation* 33 0 33
Amputations† 61 15 (11%) 46 (13%)
* Only patients with claudication preoperatively.
† Twenty-four of those had no recorded occlusion.32 patients (41% of the occlusions) this was associated
with deterioration of symptoms, compared to pre-
operative status, and in 33 (42%) an urgent reoperation
was necessary. All, except one patient, with symptom
aggravation had ePTFE grafts and all urgent reopera-
tions were performed in patients with ePTFE grafts.Amputation
There were 61 amputations reported, 15 (11%) in
patients with SV grafts and 46 (13%) in patients with
ePTFE grafts (Table 4).Analysis of patients lost to follow-up
In 56 patients, the case-records were unavailable. To
identify whether these patients differed from those
studied we used the information available in the
ordinary Swedvasc registry, where data up to 1 year
postoperatively are registered prospectively. The
mean age and the indication for surgery in this
group of patients lost to follow-up did not differ
from those included in our study. However, synthetic
grafts had been used more often (84 vs. 72%; pZ0.018).
Early failure (occlusion or death) was not significantly
different from the main study (13.7 vs. 6.8%; pZ0.074).
Mortality at 1 year was similar for the lost to follow-up
and included patients (12.5 vs. 10%; pZ0.63).Discussion
Most investigators of infra-inguinal bypass base their
life-tables on graft patency or limb-salvage rates.
However, there are other events that may be con-
sidered as procedural failures. Patients die in the
immediate postoperative period and limbs may have
to be amputated, even in the presence of a patent graft.
Moreover, patent grafts sometimes become infected
and have to be removed. Finally, an open bypass
above-knee may require a revision to below-knee
level. This is the rationale for use of the composite end-
point of graft failure.
Bypass to the popliteal artery above the knee with
SV was found to be effective for relief of claudication,
whereas bypass with ePTFE had lower success rates.
In claudicants, graft occlusion led to the development
of critical or acute ischemia in two fifths of the patients.
For patients undergoing surgery for critical ischemia,
long-term benefit of surgery was observed in two
thirds of the patients with SV grafts but in less than
half of those with ePTFE grafts. These findings are in
agreement with two of the randomized trials.4,5Eur J Vasc Endovasc Surg Vol 29, April 2005
Fig. 1. Risk of graft occlusion; Cox’s proportional hazard ratios for selected variables.
J. Berglund et al.416Therefore, our study shows that ordinary surgical care
can obtain similar results to RCTs.
This study is retrospective and patients were not
randomised. We did not control either the indication
for surgery or the choice of graft material. However,
the recorded demographic and clinical characteristics
did not differ between the two groups and with
caution the groups may be compared. The number of
patients eligible for follow-up at 5 years was greater
than in previously published RCTs3–7 and the analysis
of the patients lost to follow-up did not alter the
conclusions drawn.
The determination of graft patency is a methodo-
logical problem in retrospective studies. A graft is not
necessarily patent in patients where no occlusion has
been reported. This study defined patency as aFig. 2. Patency by indication for surgery (pZ
Eur J Vasc Endovasc Surg Vol 29, April 2005positive statement of patency in the case-records.
There was no final follow-up of graft patency for
deceased patients, allowing the possibility that results
for both graft materials were slightly better than
reported. It is unlikely that this would have affected
the conclusions drawn.
Today patients with femoro-popliteal reconstruc-
tion may enter a graft surveillance program, leading to
more frequent re-interventions in failing grafts. There-
fore, we chose primary assisted patency as the
outcome measure. However, interventions for
occluded grafts also were common, especially for
ePTFE grafts. We defined such reconstructions as
failures. The use of assisted primary patency might
favour SV reconstructions. We found that revisions
were more common in SV patients than in ePTFE0.0022). Both graft materials are included.
Fig. 3. Patency in relation to graft material for patients with critical ischemia (pZ0.031).
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tended to slightly worse. Thus, it is unlikely that the
higher rate of revisions in patients with SV grafts
resulted in an improved overall success rate.
We report similar success rates for patients operated
on with ePTFE as in previous studies, both at 2–3
years8,9,11 and 4–5 years.3,11–15 Thus, differences
between SV and ePTFE grafts could not be explained
by poor results with the synthetic graft material in this
particular study.
Since, results for SV and ePFTE grafts for treatment
of critical ischemia were similar for the first 2 years, weFig. 4. Patency by graft material for paspeculated that ePTFE might be acceptable in elderly
patients with a short life expectancy. In the subgroup
analysis of patients above 80 years of age, we found
that survival was better than anticipated. The technical
results were similar to those of younger patients. The
numbers in this very elderly groupwere small, leading
to a risk of a type II statistical error. Nevertheless, we
conclude that patients above 80 years of age should be
treated in the same manner as younger patients.
The success rate was higher for patients with
claudication than for those with critical ischemia.
Claudication usually is a symptom in patients withtients with claudication (pZ0.0027).
Eur J Vasc Endovasc Surg Vol 29, April 2005
J. Berglund et al.418limited disease, predominantly occlusion of the
superficial femoral artery, while in severe ischemia
there are coexisting lesions often at several levels. The
number of patent arteries in the lower leg was
significantly higher in claudicants than in patients
with critical ischemia, indicating a poorer run-off
situation in the latter group. Hence, the success rate in
critical ischemia being inferior, probably because the
occlusion in the thigh was not the only significant
lesion.
The reconstruction occluded in a third of the
patients with claudication and the consequences of
an occlusion were serious in a large proportion of
those patients. Occlusion, with deterioration of symp-
toms, almost only occurred among patients with
ePTFE grafts. Since, claudication is a benign condition,
this study supports the view that, for this condition,
the indications for surgery must be limited and that
the use of ePTFE should be avoided.8,11,14References
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